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Abstract
Diabetesandassociatedmetabolicconditionshavereachedpandemicproportionsworldwide,andthereisaclearunmetmedical
needfornewtherapiesthatarebotheffectiveandsafe.FGF19andFGF21aredistinctivemembersoftheFGFfamilythatfunction
as endocrinehormones.Bothhavepotent effectsonnormalizingglucose,lipid,andenergyhomeostasis,andtherefore,represent
attractive potential next generation therapies for combating the growing epidemics of type 2 diabetes and obesity. The
mechanismresponsiblefortheseimpressivemetaboliceffectsremainsunknown.WhilebothFGF19andFGF21canactivateFGFRs
1c,2c,and3cinthepresenceofco-receptorbKlothoinvitro,whichreceptorisresponsibleforthemetabolicactivitiesobservedin
vivoremainsunknown.HerewehavegeneratedavariantofFGF19,FGF19-7,thathasalteredreceptorspecificitywithastrongbias
toward FGFR1c. We show that FGF19-7 is equally efficacious as wild type FGF19 in regulating glucose, lipid, and energy
metabolisminbothdiet-inducedobesityandleptin-deficientmousemodels.Theseresultsarethefirstdirectdemonstrationofthe
central role of the bKlotho/FGFR1c receptor complex in glucose and lipid regulation, and also strongly suggest that activation of
this receptor complex alone might be sufficient to achieve all the metabolic functions of endocrine FGF molecules.
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Introduction
The FGF19 subfamily of fibroblast growth factors (FGFs),
consisting of FGF19, FGF21, and FGF23, is a novel group of
endocrine factors that have been implicated in the regulation of
many metabolic processes [1,2,3]. The subfamily members FGF19
and FGF21 share the ability to regulate glucose, lipid, and energy
homeostasis. Both FGF19 and FGF21 transgenic mice are
resistant to diet-induced obesity, have decreased adiposity and
improved insulin sensitivity, glucose disposal, and plasma lipid
profiles [4,5]. Administration of recombinant FGF19 or FGF21
protein to diabetic mice resulted in the reduction of serum glucose
and insulin levels, improved glucose tolerance, and reduced
hepatosteatosis and body weight [6,7,8,9,10,11]. In addition,
FGF21 has also been shown to induce similar beneficial changes in
rhesus monkeys [12]. These effects regarding correction of
metabolic imbalances were potent and beneficial making FGF19
and FGF21 exciting new opportunities for exploring novel
therapies to combat the growing diabetes and obesity epidemics.
The mechanisms leading to these impressive pharmacological
changes are not well understood [13,14,15,16]. One unique
property of this subfamily is their distinct requirement for co-
receptors. The paracrine-acting FGF molecules bind tightly to cell-
associated heparan sulfate glycosaminoglycans and exert their
actions by forming heparan-mediated high-affinity interactions
with FGF receptors (FGFR) thereby activating receptor tyrosine
kinases [17,18,19]. In contrast, FGF19 subfamily members have a
weak affinity toward heparan sulfate of the pericellular space
[20,21], instead, they utilize single-transmembrane-containing
Klotho proteins to facilitate their interactions with and activations
of FGFRs. There are 2 related Klotho proteins: aKlotho and
bKlotho. Both FGF19 and FGF21 utilize bKlotho for receptor
interaction and activation [13,14,15,16]. The FGFRs are encoded
by 4 genes (FGFR1–FGFR4), while alternative splicing of
FGFR1–3 further generates tissue-specific ‘‘b’’ and ‘‘c’’ isoforms
[20,21]. bKlotho interacts only with the ‘‘c’’ isoforms of FGFRs 1–
3 and with FGFR4, therefore, restricting the potential receptor
complexes that could be used by FGF19 and FGF21 as well as
restricting the potential target tissues to those sites where both
bKlotho and the appropriate FGFRs are expressed.
Both FGF19 and FGF21 activate FGFRs 1c, 2c, and 3c in a
bKlotho-dependent manner in vitro [15,22]. In addition, FGF19,
but not FGF21, can also activate FGFR4 [10,15,22]. The only
established link between a particular FGFR to physiological
functions is the connection between FGFR4 activation to bile acid
metabolism and hepatocyte mitogenesis. The involvement of
FGFR4 activation to bile acid regulation was confirmed through
the use of FGFR4 KO mice, and its involvement to hepatocyte
mitogenesis was suggested through extensive studies with FGFR4
specific FGF19 molecules and various FGF19/21 chimeras with
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33603different FGFR specificity [23,22]. Although it is believed that the
metabolic activities of FGF19 and FGF21 are probably mediated
through the activation of FGFRs1c, 2c, or 3c in the presence of
bKlotho, whether it requires activation of all three or a subset of
these receptors to achieve the glucose and metabolic effects of
FGF19 and FGF21 is not understood. If one or a subset is
sufficient to mediate these activities, which FGF receptor or
receptors contribute to the observed glucose, lipid, and energy
regulation by FGF19 and FGF21 also remains unknown.
Mitogenic activity has been observed in FGF19 transgenic mice,
which developed hepatocellular carcinoma within 12 months and
showed increased hepatocyte proliferation as early as 2 to 4
months of age [24]. The increased hepatocyte proliferation is also
observed in wild type mice injected with recombinant FGF19 for 6
days [24]. We have recently shown that the activation of liver
FGFR4 may be responsible for enhanced hepatocyte proliferation
observed with a short 6 day treatment with FGF19 [22]. However,
evidence connecting the proliferation observed in this short time
frame to tumor formation in a chronic setting is still lacking.
In the present study, we generated a variant of FGF19, FGF19-
7, that has altered receptor specificity with bias toward a bKlotho/
FGFR1c receptor complex. This novel variant has proven to be a
valuable tool in understanding which FGFR(s) are primarily
responsible for the metabolic activities of FGF19 and FGF21.
Results
FGF19-7, a FGF19 variant with receptor specificity biased
toward FGFR1c
Our previous studies suggested that the N-terminal region of
endocrine FGF molecules is important for receptor specificity
determination [25,22,26,27]. Therefore, we generated and
explored the activity of various N-terminal region chimeras
between FGF19 and FGF21 to identify novel FGF molecules
with altered receptor specificity. These investigations led to
FGF19-7, a FGF19 variant that has significantly altered receptor
specificity as compared to wild type (wt) FGF19 protein (Fig. 1).
FGF19-7 contains substitutions of FGF19 sequences from
residues 23–42 and 50–57 with the corresponding sequences from
FGF21 (Fig. 1A). The receptor specificity was studied in rat
myoblast L6 cells, which express little endogenous FGFRs, and do
not normally respond to FGF treatment. These cells were co-
transfected with FGFR1c, 2c, 3c, or 4 and bKlotho. Signaling in
response to FGF treatment was assessed by measuring phospho-
ERK (p-ERK) levels using a semiquantitative MSD assay.
Consistent with previous observations [10,22,27], while FGF19
was able to induce ERK phosphorylation with all four FGFRs (1c,
2c, 3c and 4) co-transfected with bKlotho in L6 cells, FGF21
activated only FGFRs 1c, 2c, and 3c with bKlotho but not FGFR4
(Fig. 1B). The receptor specificity profile of FGF19-7 was
significantly different from both FGF19 and FGF21. While
FGF19-7 fully activated FGFR1c/bKlotho, it had partial activity
at FGFR2c/bKlotho and lacked activity at either FGFR3c or
FGFR4 together with bKlotho (Fig. 1B). This pattern of specificity
is summarized in Table 1. Therefore, FGF19-7 is biased toward
activation of an FGFR1c/bKlotho receptor complex.
FGF19-7 showed similar metabolic efficacy to wt FGF19
in vitro and in vivo
We next tested FGF19-7 in various functional assays in vitro and
in vivo to assess the effects of altered receptor specificity on the
Figure 1. Receptor specificity for FGF19-7. (A) Schematic diagram showing FGF19 and FGF19-7. (B) L6 cells were co-transfected with expression
vectors for FGFR1c, 2c, 3c, or 4 and bKlotho. Following overnight serum starvation, cells were stimulated with vehicle, recombinant FGF19, FGF21, or
FGF19-7 for 15 min and snap frozen in liquid nitrogen. Cell lysates were prepared for MSD assay measuring ERK1/2 phosphorylation level.
doi:10.1371/journal.pone.0033603.g001
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shown that FGF19 can stimulate glucose uptake by adipocytes
[15,10,22,26], therefore, we first tested the effect of FGF19-7 in a
glucose uptake assay using differentiated mouse 3T3-L1 adipo-
cytes. As shown in Fig. 2A, FGF19-7 stimulated glucose uptake in
adipocytes to a similar extent as FGF19 suggesting that the altered
receptor specificity had no impact on this particular function of
FGF19.
We further tested the ability of FGF19-7 to regulate glucose
metabolism in vivo in both a diet-induced-obesity (DIO) murine
modelaswellasleptin deficient ob/obmice.Fourteen-week-old male
B6D2F1 mice, fed a high-fat diet for 8 weeks, were divided into 3
groups (n=12) based on initial body weight and glucose. Mice were
then injected intraperitoneally (i.p.) with PBS, 1 mg/kg FGF19, or
1 mg/kg FGF19-7 daily for a period of 2 weeks. Compared to wild
type FGF19, FGF19-7 showed equal reduction in body weight
throughout the study (Fig. 2B), and equal reduction in plasma
insulin (Fig.2D) and triglyceride(Fig.2E)levels atthe termination of
the study. The FGF19-7 group also showed a slightly better
reduction in fasting glucose level compared to wild type FGF19.
While significant reduction was achieved at 7 days post treatment
withFGF19-7,nosignificantchangeswere observedinthewild type
FGF19 treated group until day 14 (Fig. 2C). An oral glucose
tolerance test (OGTT) was performed at the end of the 2-week
treatment to assess the ability of the animals to dispose a glucose
challenge. As shown in Fig. 2F, both FGF19-7 and FGF19
treatments significantly improved the responses of these animals
to the oral glucose challenge (OGTT) to a similar extent.
A similar study was also carried out with ob/ob mice, whereby
FGF19-7 showed equal efficacy to wild type FGF19 in lowering
fasting plasma glucose levels and improving OGTT (data not
shown). Similar or greater effects on the reduction of body weight
Table 1. Receptor specificity for FGF19, FGF21, and FGF19-7.
FGF molecules Receptors
FGFR1c/bKlotho FGFR2c/bKlotho FGFR3c/bKlotho FGFR4/bKlotho
FGF19 ++ ++ ++ ++
FGF21 ++ ++ ++ 2
FGF19-7 ++ + 2 2
++indicates strong activity.
+indicates weak activity.
2indicates no activity.
doi:10.1371/journal.pone.0033603.t001
Figure 2. Effects of FGF19-7 on adipocyte glucose uptake and metabolic parameters in DIO mice. (A) Differentiated 3T3-L1 adipocytes
were incubated for 72 h with FGF19 or FGF19-7 and assayed for glucose uptake. (B–F) Mice were injected with recombinant FGF19, FGF19-7 protein
daily intraperitoneally at 1 mg/kg body weight or an equal volume of PBS control. Body weight (B) and fast glucose (4 hr fasting) (C) were measured 2
days before and 7 or 14 days after IP daily injection. After 14 days, an oral glucose tolerance test (OGTT) (F) was performed by administering 2 g/kg of
glucose to each mouse and measuring serum glucose concentration at the indicated time points. Serum insulin (D) and triglyceride (E) levels were
measured after 4 hr fasting. Values are means 6 SEM of 12 mice/group. **P,0.01 and ***P,0.001, t-test.
doi:10.1371/journal.pone.0033603.g002
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group as compared with the wild type FGF19 group. Taken
together, these results suggest that the ability of FGF19-7 to
regulate glucose metabolism and to induce body weight reduction
were unaffected despite the changes in receptor specificity.
FGF19-7 lost the ability to induce mitogenesis and FGFR
signaling in the liver
Besides the ability to regulate glucose metabolism, FGF19 has
also been shown to induce hepatocyte proliferation mediated
through the activation of liver expressed FGFR4 [24,22,26]. Since
FGF19-7 lost the ability to activate FGFR4, we tested its effects on
the induction of hepatocyte mitogenesis as well as activation of
liver FGFR signaling.
The effects of FGF19-7 on hepatocyte proliferation was tested
using an in vivo BrdU labeling method similar to that described
previously [24,22,26]. As shown in Fig. 3A and 3B, histopatho-
logical examination of liver sections from FGF19 treated animals
showed increased BrdU-labeled hepatocytes concentrating in
centrilobular regions of hepatic lobules, consistent with previously
published observations [24,22,26]. In contrast, livers from FGF19-
7 treated animals did not show increased BrdU labeling in
hepatocytes in the pericentral regions, nor was increased BrdU
incorporation noted in any other area of the liver. These results
suggest that the FGF19 variant, FGF19-7, does not promote
hepatocyte proliferation.
The FGFR signaling induced by FGF19 and FGF19-7 was
directly measured in these animals as well. At the end of the 7 day
study, liver and adipose tissue were collected 15 min following the
final dose of FGF19 or FGF19-7 injection and ERK phosphor-
ylation was measured by Western blot analysis (Fig. 3C).
Consistent with the ability of both molecules to stimulate glucose
uptake by 3T3-L1 adipocytes which mainly express FGFR1c
(Fig. 2A), FGF19 and FGF19-7 stimulated ERK phosphorylation
to a similar extent in adipose tissue in vivo (Fig. 3C left panel). In
contrast, while wild type FGF19 induced robust signaling in the
liver, no significant ERK phosphorylation was observed in livers
from FGF19-7-treated mice. This is consistent with the notion that
FGF19-7 lacks activity at FGFR4 which is the predominant
receptor expressed in the liver (Fig. 3C right panel) and directly
correlates with its inability to promote liver BrdU incorporation in
vivo.
One year study with FGF19-7 using AAV gene delivery
The ability of FGF19 to induce hepatocyte proliferation
observed in the BrdU incorporation studies has been suggested
as the cause for the eventual development of hepatocellular
carcinomas in FGF19 transgenic mice [24]. Because FGF19-7
does not induce hepatocyte proliferation, it could be used as a tool
to test the link between BrdU incorporation observed by acute
FGF19 treatment in a 1-week study to the long term effect of
tumor development.
The observation that FGF19 induced liver tumors was made
with a transgenic model, thus potential developmental contribu-
tions of the transgene to tumor formation could not be ruled out.
Stable long term expression of up to 1 year has been observed with
Figure 3. Effects of FGF19-7 on signaling and proliferation in liver in vivo. (A) BrdU immunostaining of livers from female FVB mice after
BrdU infusion by osmotic minipump. Mice received daily injections of PBS (left), 2 mg/kg/day recombinant FGF19 (middle), or 2 mg/kg/day FGF19-7
(right) for 6 consecutive days beginning on day 2 of the study. Stained nuclei of hepatocytes in the liver from the FGF19 treated mouse are oriented
around central veins (c) and away from portal veins (p). Hematoxylin counterstain. (B) Semiquantitative analysis of BrdU-positive hepatocytes from
(A). The scores assigned to BrdU incorporation for these animals were based on a semiquantitative scale described in the Materials and Methods
section. Solid bars represent group mean score with standard error (n=8 for each group). (C) Liver and adipose tissue (epididymal fat) were excised
from female FVB mice (four animals per group) treated with PBS, 10 mg/kg FGF19 (F-19) or FGF19-7 (F19-7) 15 min post injection. Tissue lysates were
prepared and pooled for Western blot analysis using phosphorylated ERK1/2 (pERK) or total ERK1/2 (tERK) antibodies.
doi:10.1371/journal.pone.0033603.g003
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tions). We decided to assess the long term effect with respect to
tumor formation of sustained expression of FGF19 and FGF19-7
using AAV as a gene delivery vehicle. Additionally, in order to
obtain information on the metabolic benefits of FGF19 and
FGF19-7 in an adult on-set model of obesity, B6D2F1/J male
mice were first put on high fat diet at 3–4 weeks old prior to AAV
virus injection. The study was carried out for 1 year with periodic
measurements of body weight and glucose. At the conclusion of
the study, body weight, liver weight, plasma glucose, OGTT, TG,
insulin, and FGF19 levels were measured. In addition, the
proliferation state of hepatocytes was assessed by implantation of
a minipump containing BrdU one week prior to termination by a
procedure similar to the study shown in Fig. 3A and histopath-
ologic evaluation of liver sections was performed.
During the course of the 1 year study, mice injected with AAV
expressing FGF19-7 had reduced body weight gain similar to the
group receiving AAV expressing wild type FGF19 (Fig. 4A). The
fasting glucose levels were not significantly different between all
groups (data not shown), however, mice receiving AAV virus
expressing FGF19 and FGF19-7 significantly improved their
response to an oral glucose challenge (Fig. 4B). In addition, at
the termination of the study, both FGF19 and FGF19-7 groups
had significantly lowered plasma TG and insulin levels
compared to control, consistent with results from the short term
studies (Fig. 2) and previously published effects of FGF19 on
metabolism. These observations further verified that selective
activation of an FGFR1c/bKlotho receptor complex was
sufficient to elicit the metabolic regulation observed with wild
type FGF19.
The morphology of the livers from the 3 treatment groups
showed dramatic differences. Livers from control AAV virus
treated mice were pale consistent with accumulation of fat in
hepatocytes from high fat feeding. This was visualized as
cytoplasmic vacuolation (arrows, Fig. 5A top panel) in the H&E-
stained liver sections from mice inoculated with AAV-Control
virus. While animals receiving AAV-FGF19 virus lacked signs of
lipid accumulation in liver (Fig. 5A, top panel), gross morpholog-
ical changes with multiple nodules or masses were observed in
their livers consistent with the formation of liver tumors. AAV-
FGF19 virus treated animals also showed a dramatic increase in
liver weight compared to the other two groups (Fig. 5C). In
contrast, the livers from AAV-FGF19-7 virus treated animals had
normal gross morphology and no fat accumulation was observed
(Fig. 5A).
Sections of H&E stained livers from these mice (Fig. 5A, top
panel) were evaluated for the presence of tumors and lesions
considered preneoplastic such as foci of hepatocellular alteration
and intravenous protrusion of hepatocytes. In addition, BrdU
staining was carried out to evaluate hepatocellular proliferation
(Fig. 5A, bottom panel). The sections stained for BrdU
incorporation were taken from an area near to the paired section
stained with H&E and the photographs show the same portal (p)
and central (c) veins. Benign or malignant tumors were present in
4 of the 11 AAV-control mice and a focus of cellular alteration was
present in one additional mouse from this group. This could be
Figure 4. Metabolic parameters in DIO mice after 1 year treatment with FGF19-7. (A) Body weight. Mice receiving FGF19 and FGF19-7
remained leaner than control 13 months after AAV injection. Eleven months after AAV administration, oral glucose tolerance test (OGTT) (B) was
performed by injecting mice with 2 g/kg of glucose and measuring serum glucose concentration at indicated time points. Triglyceride (C), insulin (D)
and serum human FGF19 levels (E) were measured after 4 hr fasting prior to termination of the study. Values are means 6 SEM of 10–15 mice/group.
**P,0.01 and ***P,0.001, t-test.
doi:10.1371/journal.pone.0033603.g004
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ment of liver tumors when fed a high-fat diet [29,30]. Nine of the
10 mice inoculated with AAV-FGF19 displayed benign hepatic
tumors (hepatocellular adenoma; 6 mice), malignant hepatic
tumors (hepatocellular carcinoma; 7 mice) or both (4 mice).
Preneoplastic hepatocellular lesions (foci of hepatocellular alter-
ation, intravenous protrusion of hepatocytes or both) were noted in
8 of these 10 mice including the one mouse in this group that
lacked a hepatocellular tumor (Fig. 5D). Examination of non-
tumor bearing portions of the liver showed that hepatocytes
around central veins in the H&E-stained sections of livers from
mice inoculated with AAV-FGF19 were crowded, slightly smaller,
and had increased cytoplasmic basophilia when compared with
hepatocytes in the same area of livers from mice inoculated with
AAV-FGF19-7 (Fig. 5A). Remarkably, none of the livers from the
11 mice inoculated with AAV-FGF19-7 exhibited tumors or
preneoplastic lesions.
Immunohistochemistry for BrdU incorporation showed that
mice inoculated with AAV-FGF19 incorporated BrdU tightly
restricted to hepatocytes around the central vein similar to
observations in mice acutely treated with recombinant FGF19
protein for 6 days (Fig. 5A bottom panel). This was not seen in
mice that received control AAV or AAV-FGF19-7 constructs.
Mice inoculated with AAV-FGF19-7 exhibited equivocally to
minimally increased numbers of BrdU-labeled hepatocytes
compared to the AAV control group, but these lacked orientation
to central veins or other portions of the hepatic lobules. However,
given that the metabolic homeostasis and, in particular, the state of
the liver between these two groups are dramatically different, i.e.
the AAV control group exhibited steatosis not seen in the FGF19-7
group, it was difficult to conclude whether these differences could
contribute to background BrdU signals. More importantly, the
pericentral BrdU staining seen in the wild type FGF19 group was
absent in the FGF19-7 group and no tumor formation was
observed in the latter indicating that the FGF19 variant had lost
the ability to induce liver tumor formation.
Discussion
FGF19 and FGF21 are unique members of the FGF family and
have been shown as novel hormones that can regulate glucose,
lipid, and energy metabolism. Their potent effects on improving
glucose disposal, insulin sensitivity, plasma lipid parameters, and
on inducing body weight loss are very similar between these two
endocrine FGFs and have been reported in multiple models of
diabetes and obesity in rodents and non-human primates.
However, the underlying mechanisms leading to these metabolic
benefits are not well understood.
Not only do FGF19 and FGF21 share similar in vivo
pharmacology with respect to glucose regulation, they also share
many similarities in receptor activities. Both FGF19 and FGF21
have reduced or no affinity to heparan sulfate and use a single pass
transmembrane protein bKlotho to interact with and to activate
FGFRs [13,15,14]. In cell based assays in vitro, both FGF19 and
Figure 5. Liver phenotype of DIO mice after 1 year treatment with FGF19 and FGF19-7. (A) Liver sections from mice inoculated 1 year
prior with AAV-Control (left panel), AAV-FGF19 (middle panel), or AAV-FGF19-7 (right panel) virus and stained with H&E (top panel) or by an
immunohistochemical method to visualize BrdU incorporation as a marker for DNA synthesis and mitosis (bottom panel). The sections stained for
BrdU incorporation were taken from an area near to the paired section stained with H&E and show the same portal (p) and central (c) veins.
Centrilobular to midzonal hepatocytes in the H&E-stained section of liver from the mouse inoculated with AAV-Control show cytoplasmic vacuolation
(arrows) that likely reflects fat accumulation due to consumption of a high fat diet. Mice inoculated with AAV-FGF19 or AAV-FGF19-7 were resistant to
this effect of the high fat diet. Hematoxylin counterstain (bottom panel); all photographs 1006. (B) Semiquantitative analysis of BrdU-positive
hepatocytes from (A bottom panel). (C) Liver weight comparison between the different groups. (D) Quantitative counts of number of tumors present
in the different groups at the end of the 1 year study.
doi:10.1371/journal.pone.0033603.g005
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bKlotho. The only difference in receptor utilization reported for
these two FGFs is that FGF19, but not FGF21, can activate
FGFR4 [31]. Therefore, it was known that both FGF19 and
FGF21 can activate multiple FGF receptor complexes in vitro;
however, their metabolic activity, such as regulation of glucose
metabolism, had not been clearly ascribed to a specific FGFR/
bKlotho complex prior to this study.
To identify the receptor or receptors responsible for the
metabolic activities of FGF19 and FGF21, we took the approach
to generate FGF19 or FGF21 variants that selectively activate one
or a subset of the FGFRs. We previously demonstrated that such
an approach is feasible with the generation of an FGF19 variant,
FGF19dCTD, which is a specific activator of FGFR4 [10]. In the
diabetic ob/ob mouse model, we showed that selective activation
of FGFR4 was not sufficient to improve glucose metabolism
suggesting that other receptors must be important for the
regulation of glucose homeostasis [10]. Because the primary
difference between FGF19 and FGF21 is the ability of FGF19 to
activate FGFR4, yet both have similar effects on glucose
metabolism, these results suggest that the metabolic effects of
FGF19 and FGF21 are likely mediated through a similar
mechanism and through receptors other than FGFR4. Therefore,
the understanding of FGF19 induced metabolic effects such as
glucose regulation could be translated to FGF21 and vice versa.
Because we recently showed that the N-terminal regions of
FGF19 and FGF21 are important for receptor specificity
determination [31], we explored various N-terminal mutations
to generate an FGF variant that can selectively activate FGFR1c,
2c, or 3c, the 3 receptors commonly activated by FGF19 and
FGF21, in complex with bKlotho. From many different variants
we have tested, FGF19-7 was identified to have a receptor
specificity biased toward the FGFR1c/bKlotho complex. Despite
receptor specificity significantly altered from FGF19, FGF19-7 was
equal to or better than wild type FGF19 at increasing glucose
uptake into adipocytes in vitro and at reducing body weight,
plasma insulin, glucose, and TG levels, and at improving glucose
disposal in both diet induced obesity and ob/ob mice models.
These results provide the first strong in vivo evidence that the
FGFR1c/bKlotho receptor complex may be the main, if not the
sole receptor complex that mediates the metabolic effects of
FGF19 and by extension, FGF21 as well. Consistent with the
expression of FGFR1c being predominately in adipocytes among
the bKlotho expressing cells, FGF19-7 was only able to activate
FGFR signaling in fat but not liver (Fig. 3C). This suggests that fat
maybe the primary target tissue for the metabolic functions of
FGF19 and FGF21.
In addition to its ability to regulate glucose metabolism, FGF19
was reported to induce hepatocyte proliferation. This conclusion
was based on the observation that BrdU incorporation increased
in the liver of animals injected with FGF19 protein for 6 days,
especially in hepatocytes adjacent to central veins [24]. In a
chronic setting, hepatocellular carcinoma (HCC) formation was
observed in 8–10 month old FGF19 transgenic mice [24]. It was,
therefore, suggested that the induction of hepatocyte proliferation
observed in the relatively short BrdU study was responsible for the
formation of HCC in the FGF19 transgenic animals [24]. We
previously showed that the hepatocyte proliferation observed in
the short term studies is due to activation of liver FGFR4 receptor
by FGF19 [22,26], however, no direct link between short-term
BrdU labeling and long-term HCC formation was previously
established.
Because FGF19-7 does not activate FGFR4 (Fig. 1B), its effect
on hepatocyte proliferation and on HCC formation were studied.
In contrast to FGF19 treated animals, mice receiving recombinant
FGF19-7 protein for 7 days did not show increased BrdU labeled
hepatocytes in the pericentral region or in any other areas of liver
(Fig. 3). The effect of FGF19 versus FGF19-7 on liver tumor
formation was also studied utilizing AAV gene delivery method to
introduce these proteins into mice starting at 4-weeks age.
Sustained expression of FGF19 or FGF19-7 was observed in our
study after 1 year (Fig. 4E). The animals were also subjected to a
high fat diet during the 1 year treatment, such that their long term
effect on metabolism could also be monitored. At the end of the
long-term study, similar to the 2 week study, FGF19-7 showed
effects equal to or better than FGF19 on reducing the body weight
gain and elevated plasma insulin and TG levels caused by the
high-fat diet. Improved glucose disposal was also observed (Fig. 4).
However, a major difference between the FGF19 and FGF19-7
groups was that the FGF19 group developed liver tumors, while no
liver tumors were observed in the AAV-FGF19-7 group (Fig. 5).
Our method, using AAV-FGF19-treated mice, confirmed that
chronic exposure to FGF19 as observed in the FGF19 transgenic
mice causes formation of hepatocellular tumors. In addition, the
lack of liver tumors in the FGF19-7 group further establishes the
connection of FGFR4 activation and enhanced BrdU labeling in
short-term studies to liver tumor formation in long-term studies.
Interestingly, liver tumors were also observed in the AAV control
group on a high fat diet. This suggests that FGF19-7, either
through the beneficial metabolic effects or directly, suppressed or
protected these animals from the development of hepatocellular
tumors.
Taken together, these results not only confirmed that the
activation of the FGFR1c/bKlotho receptor complex is not
expected to induce hepatocyte proliferation and HCC formation,
but further established its central role in mediating the metabolic
activities of FGF19 and FGF21.
Materials and Methods
Cell culture and transfections
L6 cells (obtained from American Type Culture Collection)
were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and penicillin/
streptomycin. Cells were transfected with expression vectors
harboring FGF19 and variants by using the Lipofectamine 2000
transfection reagent (Invitrogen) according to the manufacturer’s
protocol.
MSD assay and Western analysis for FGF signaling
Briefly, L6 cells were plated, transfected with FGF receptors and
treated with various FGF molecules as previously described [10].
Cells were collected 15 min after treatment, snap frozen in liquid
nitrogen, lysed in the lysis buffer, and the total and phosphorylated
ERK were measured by using an MSD whole cell lysate Phospho-
ERK1/2 kit (Meso Scale Discovery) according to the manufac-
turer’s instructions. All experiments were run in duplicates.
In vivo hepatocyte BrdU labeling
In vivo BrdU labeling studies were carried out as previously
described [22]. On day 1 of the short-term labeling study, an
osmotic minipump (ALZETH, model 1007D) containing 5-bromo-
29-deoxyuridine (BrdU; Sigma Chemical Co., St. Louis, MO)
(16 mg/mL) was implanted subcutaneously. Samples of liver and
duodenum were collected from each mouse on day 7 after the
minipump implantation and placed in 10% neutral-buffered
formalin in preparation for paraffin-embedding, sectioning, and
light microscopic evaluation. The section of duodenum was
FGFR1c/b-Klotho in Metabolic Regulation
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and for the BrdU immunohistochemical staining procedure since
the epithelium of this tissue has a rapid turnover rate and should
show complete labeling for BrdU incorporation after 7 days of
exposure to BrdU. Sections of all collected tissues were stained by
an immunohistochemical method to visualize BrdU incorporation
as a marker of mitotic activity. Tissue sections were examined at
random by routine light microscopy without knowledge of
treatment group. The number of hepatocyte nuclei stained for
BrdU incorporation was assigned a score on a semiquantitative
scale as follows: 0= no increase above expected levels in vehicle-
treated (control) mice and 6= equivocal, 1= minimal, 2= mild,
3= moderate, and 4= marked increase above control levels. The
localization (centrilobular or diffusely scattered through hepatic
lobules) of the hepatocytes stained for BrdU incorporation was also
recorded. Only hepatocyte nuclei (large, round nuclei clearly
within hepatocytes) were considered for semiquantitative scoring
of BrdU labeling. Nuclei of other cells types (e.g., bile duct
epithelium, Kupffer cells, endothelial cells, and infiltrating
leukocytes) were sometimes labeled with BrdU; however, these
cells and their nuclei are morphologically distinct from hepatocytes
and hepatocyte nuclei and have different anatomic localizations.
These nuclei were not considered for the scoring of BrdU labeling
in hepatocytes. Labeling with BrdU in the long-term AAV study
was done in the same manner. The BrdU-containing minipump
was implanted 7 days before collection of tissues.
Mice and treatment
All animal experiments were approved by the Institutional
Animal Care and Use Committee of Amgen. Mice were housed in
an air-conditioned room at 2262uC with a 12 h light: 12 h
darkness cycle (0600–1800 h). Male B6D2F1 mice were purchased
from Charles River. Two days before AAV injection, cohorts of 4-
week-old mice (n=15) were sorted by body weight and fasting
glucose levels. Indicated adeno-associated virus (AAV) in 200 mlo f
PBS was administrated via the tail vein with a U-100 insulin
syringe. The dose was 8610
12 virus particles per mouse. After
AAV administration, all the mice were put on BioServe 1850 high-
fat diet (60 kcal % fats) through the end of study.
Fourteen-week-old male B6D2F1 mice fed with Research Diets
D12492 (60 kcal % fat) for 8 weeks were purchased from Jackson
Laboratory. Two days before protein injection, mice were divided
into 3 groups (n=12) based on body weight and glucose. Starting
from day0, mice were intraperitoneally-injected daily with
recombinant FGF19 or FGF19-7 protein in 0.2 ml PBS (each at
1 mg/kg body weight) or same volume of PBS control. OGTT
was done on day7 and 14, following 4 hr fasting. Terminal bleeds
were taken at day15, following 6 hr fasting.
Glucose tolerance tests and plasma insulin, triglyceride
and FGF19 measurement
Mice were fasted for 4 hr beginning at 6 am on the day of the
experiment.Blood samples obtained from the tailvein wereused for
insulin, triglyceride and FGF19 measurements. Following admin-
istration of glucose (2 g per kg oral gavage), glucose levels were
measured immediately predose, 15, 30, and 60 min after glucose
injection by using Accu-chek Aviva blood glucose meter (Roche
Diagnostic). Plasma insulincontent was determinedby using Insulin
(mouse) ultra-sensitive EIA kit (ALPCO Diagnostics, 80-INSMSU-
E10). Plasma triglyceride was measured by using Serum Triglyc-
eride DeterminationKit (Sigma, TR0100). PlasmaFGF19 level was
determined by an in house ELISA assay using polyclonal Anti-
human FGF19 antibody and Biotinylated anti-human FGF19
antibody (R&D systems, Catalog # AF969 and # BAF969).
Western-blot analysis of the FGF signaling pathway
Liver and adipose tissue were collected 15 min after injection of
indicated proteins and snap frozen in liquid nitrogen. After
homogenization in lysis buffer, liver and fat samples were
separated on 4–15% polyacrylamide gels (Bio-Rad) and trans-
ferred to nitrocellulose membranes (0.45 mM, Bio-Rad). Mem-
branes were blocked (5% non-fat dry milk in 0.05% Tween-PBS)
and incubated with a polyclonal anti-rabbit/phospho-ERK
antibody (1:2000, Cell Signaling #9101). Bound antibody was
detected by peroxidase-conjugated secondary antibody and
visualized using SuperSignal West Pico Chemiluminescent
Substrate (Pierce Biotechnology). The same membranes were
washed and used for total ERK analysis by using anti-rabbit/ERK
antibody (1:2000, Cell Signaling #9102).
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